Yajie Kong

Yajie Kong

Auto-generated profile, based on publicly available information

Yajie Kong

Department of Orthopedics, The Second Hospital of Hebei Medical University, Shijiazhuang, P. R. China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2025 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
YWYuzhong Wang
Yuzhong Wang
YKYajie Kong
Yajie Kong
JDJiejie Du
Jiejie Du
LQLifei Qi
Lifei Qi
MLMeiling Liu
Meiling Liu
YSYongzhou Song
Yongzhou Song
Background: Background: Exosomes (Exos) derived from mesenchymal stem cells (MSCs) share similar biological functions with MSCs but are more stable under various pathophysiological conditions, with a lower risk of immune rejection. Human umbilical cord mesenchymal stem cells (hUC-MSCs) are a promising source of MSC-derived exosomes (MSC-Exos), particularly for the treatment of osteoarthritis (OA), a degenerative joint disease characterized by inflammation and cartilage damage. Methods: In this study, we conducted in vitro experiments on mouse articular chondrocytes and treated mouse OA models with hUC-MSCs-Exos. To validate the results of hUC-MSCs-Exos in humans, a randomized, double-blind, ascending dose study was conducted to investigate the safety and efficacy of hUC-MSCs-Exos in the treatment of OA, and human chondrocyte toxicity experiments were conducted prior to the clinical trial. Results: In this study, we successfully extracted hUC-MSCs and verified their multilineage differentiation ability in different culture media. We then verified the Exos morphology and the expression of CD9, CD63, TSG1, and CALN. In preclinical experiments in vitro and in vivo, we verified that hUC-MSC- Exos can reduce the inflammatory response of articular cartilage and promote its regeneration. Finally, clinical experiments confirmed that hUC-MSC- Exos injection treatment of OA patients did not cause any adverse consequences, and a certain degree of effectiveness was found in the comparison of clinical scores and MRI examinations before and after treatment. Conclusions: This study shows that hUC-MSC-derived exosomes effectively reduce inflammation and promote cartilage regeneration in osteoarthritis, with demonstrated safety and efficacy in both preclinical and clinical settings. Trial registration: Trial No.MR-13-24-017929. Registered 11 February 2023, https://medicalresearch.org.cn/login#.

18 December 2024 in Journal of Orthopaedic Surgery and Research
Verified
Journal Article
Open access
PDF file
YKYajie Kong
Yajie Kong
YWYuzhong Wang
Yuzhong Wang
YYYujia Yang
Yujia Yang
YHYu Hou
Yu Hou
JYJingjing Yu
Jingjing Yu
YSYongzhou Song
Yongzhou Song
In recent years, the increasing incidence of osteoarthritis (OA) has attracted widespread public attention; however, the available effective treatments are limited. As a result, new therapeutic approaches, including stem cell and exosome therapies, have been proposed and are gradually gaining popularity. Because exosomes are immunocompatible, there is thought to be more potential for their use in clinical settings. This study summarizes the efficacy of exosomes in the treatment of OA. In total, we conducted a comprehensive search of the PubMed, Web of Science, and Embase databases using medical subject headings terms to identify studies published from their inception until November 2023 that investigated the use of stem cell-derived exosomes in treating OA. We focused on specific outcomes including osteophyte score, chondrocyte count, pain level, qPCR and histological assessments such as the OARSI (Osteoarthritis research society international) score to measure cartilage degeneration. For data extraction, we used GetData Graph Digitizer to retrieve values from graphs, and the meta-analysis was conducted using RevMan 5.3 software. We chose mean difference (MD) as the primary effect measure since all included studies reported the same outcomes. Ultimately, 20 articles met the inclusion criteria and were included in the meta-analysis. We evaluated 20 studies comprising a total of 400 subjects. Compared with control groups, the exosome-treated groups showed significantly improved histological outcomes, as measured by the OARSI score (n = 400; MD = −3.54; 95% CI = [−4.30, −2.79]; P < 0.00001; I2 = 98%). This indicates a marked reduction in cartilage degeneration and OA severity in the exosome-treated groups. Notably, exosome therapy was more effective when administered during the early stages of OA. Additionally, a once-weekly dosing schedule yielded better results compared to more frequent administrations. Of the three exosome isolation methods assessed, kit-based extraction demonstrated a trend toward superior therapeutic efficacy. Exosome treatment improved OA compared to placebo treatment.

1 January 2025 in Stem Cells International
Verified
Journal Article
Open access
MLMeiling Liu
Meiling Liu
SXSiyi Xie
Siyi Xie
YKYajie Kong
Yajie Kong
YYYiming Yang
Yiming Yang
RCRuixue Chen
Ruixue Chen
YSYongzhou Song
Yongzhou Song
Background: In recent years, the incidence rates of type 2 diabetes mellitus (T2DM) and osteoarthritis (OA) have increased significantly. Currently developed therapeutic approaches (e.g., pharmacotherapy) exhibit limited efficacy in the treatment of T2DM and OA, failing to fully restore joint function and pancreatic islet function. Mesenchymal stem cells (MSCs) have demonstrated substantial potential in repairing cartilage damage, reducing blood glucose levels, and other related aspects. Objective: This review aims to evaluate whether MSC therapy represents a potential therapeutic strategy for T2DM complicated with OA. Summary: This review highlights the association between OA and T2DM and summarizes the applications of MSCs in the treatment of OA and T2DM, the potential mechanisms of MSCs, as well as relevant therapeutic strategies. Conclusion: MSC therapy may exert therapeutic effects in models of T2DM complicated with OA. This approach is expected to serve as an innovative and effective therapeutic method, promoting research on stromal cells and their applications. However, further studies are still required to verify its safety and feasibility.